Therapy, treatment, and process for photodynamic inactivation of COVID-19
OwnerHugh McGrath, Jr.inventor
Life of this patent
Estimating the term…
Abstract
A therapy, treatment and process for inactivating and/or killing COVID-19 (Corona Virus Disease 2019) is provided, including a low-dose, full body, Ultraviolet A1 (UV-A1, 360-400 nm) photon therapy, wherein the UV-A1 photon therapy activates singlet oxygen (1O2), which inactivates and/or kills COVID-19. UV-A1 therapy of the present invention can also be used to help alleviate symptoms and secondary illnesses caused by COVID-19. UV-A1 therapy of the present invention can also be used to help alleviate and treat pre-existing conditions of people that are also suffering from COVID-19 and worsened by COVID-19.
Claims20
A systemic phototherapy treatment and process for a patient suffering from Corona Virus Disease 2019 (COVID-19), comprising the following steps:
- using an irradiator to systemically treat the COVID-19 or secondary conditions caused by the COVID-19 by externally subjecting at least a substantial portion of a patient's body to one or more wavelengths of UV-A1 light in a range of 340 to 400 nm at 6-15 J/cm2/day for a selected time interval and at more than one selected time.
A method of treating a patient suffering from Corona Virus Disease 2019 (COVID-19), comprising the steps of:
- (a) externally subjecting at least a substantial part of skin of the patient to one or more wavelengths of UV-A1 light in a range of 340 to 400 nm at 6-15 J/cm2/day for a selected time interval and at multiple selected times;
- (b) wherein step (a) includes emitting radiation from an irradiator lamp with a filter that allows emission of UV-A1 photons while at least substantially excluding other harmful photons;
- and
- wherein the UV-A1 light reaches a sub dermis, along the way reaching infiltrating macrophages and cells circulating in dermal and subdermal capillaries where the UV-A1 light triggers production of singlet Oxygen, which activates a gene for heme oxygenase, which releases from heme carbon monoxide, biliverdin and bilirubin to target the COVID-19 and reduce or eliminate inflammatory responses or secondary conditions caused by the COVID-19.
A systemic phototherapy treatment and process for alleviating one or more symptoms or side effects or secondary illnesses caused by Corona Virus Disease 2019 (COVID-19) including post COVID-19 conditions, for a patient who is or has suffered from COVID-19, includes the following steps:
- using an irradiator to treat the symptoms or secondary illnesses by subjecting at least a substantial portion of skin of the patient to one or more wavelengths of UV-A1 light in a range of 340 to 400 nm at 6-15 J/cm2/day for a selected time interval for a selected date range;
- and
- wherein the UV-A1 light is absorbed by a sub dermis, along the way reaching infiltrating macrophages and cells circulating in dermal and subdermal capillaries where the UV-A1 light triggers production of singlet oxygen, which activates a gene for heme oxygenase, which produces carbon monoxide to target the COVID-19 and/or reduce inflammatory responses caused by the COVID-19 and other inflammatory conditions.
Dependencies are inferred from the claim text.